Irinotecan
MTAP Deletion
Tango Therapeutics, Inc.Small moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
8 Active assets in the MTAP Deletion cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
tng462 Tango Therapeutics, Inc. | Phase 1/2 | CC |
Eloxatin Tango Therapeutics, Inc. | Phase 1/2 | CC |
FLUOROURACILUM Tango Therapeutics, Inc. | Phase 1/2 | CC |
Rmc-6236 Tango Therapeutics, Inc. | Phase 1/2 | CC |
Rmc-9805 Tango Therapeutics, Inc. | Phase 1/2 | CC |
Calcium folinate pentahydrate Tango Therapeutics, Inc. | Phase 1/2 | CC |
pep08 PharmaEngine | Phase 1 | CC |
hs-10587 Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 | NR |
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →